Assyro AI

Orange Book product · Brand (NDA)

ONPATTRO

PATISIRAN SODIUM

Brand (NDA)NDA 210922RX ALNYLAM PHARMS INC

At a glance

Aug 10, 2018

Approved

Brand (NDA)

Application

Not listed

TE code

13

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Aug 10, 2018

    8 yr ago

  2. Exclusivity ends · M-270

    New use / labeling-change exclusivity (3 years)

    Jan 13, 2026

    5 mo ago

  3. Today

  4. Patent 8642076 expires

    Listed drug product patent expiration.

    Oct 03, 2027

    in 1 yr 4 mo

  5. Patent 11141378 expires

    Listed drug product patent expiration.

    Apr 15, 2029

    in 2 yr 10 mo

  6. Patent 8058069 expires

    Listed drug product patent expiration.

    Apr 15, 2029

    in 2 yr 10 mo

  7. Patent 8492359 expires

    Listed drug product patent expiration.

    Apr 15, 2029

    in 2 yr 10 mo

  8. Patent 8822668 expires

    Listed drug product patent expiration.

    Apr 15, 2029

    in 2 yr 10 mo

  9. Patent 9364435 expires

    Listed drug product patent expiration.

    Apr 15, 2029

    in 2 yr 10 mo

  10. Patent 10240152 expires

    Listed drug substance patent expiration.

    Oct 20, 2029

    in 3 yr 5 mo

  11. Patent 8741866 expires

    Listed method-of-use patent (U-2378) expiration.

    Oct 20, 2029

    in 3 yr 5 mo

  12. Patent 9234196 expires

    Listed drug product patent expiration.

    Oct 20, 2029

    in 3 yr 5 mo

  13. Patent 8802644 expires

    Listed drug product patent expiration.

    Oct 21, 2030

    in 4 yr 5 mo

  14. Patent 8158601 expires

    Listed drug product patent expiration.

    Nov 10, 2030

    in 4 yr 6 mo

  15. Patent 8168775 expires

    Listed drug substance patent expiration.

    Aug 10, 2032

    in 6 yr 3 mo

  16. Patent 11079379 expires

    Listed drug substance patent expiration.

    Aug 27, 2035

    in 9 yr 4 mo

Pharmaceutical detail

Active ingredient

PATISIRAN SODIUM

Strength

EQ 10MG BASE/5ML (EQ 2MG BASE/ML)

Dosage form

SOLUTION

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 210922

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

  • M-270New use / labeling-change exclusivity (3 years)

    Jan 13, 2026

    5 mo ago

Listed patents (13)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8642076Oct 03, 2027in 1 yr 4 mo
Product
11141378Apr 15, 2029in 2 yr 10 mo
Product
8058069Apr 15, 2029in 2 yr 10 mo
Product
8492359Apr 15, 2029in 2 yr 10 mo
Product
8822668Apr 15, 2029in 2 yr 10 mo
ProductU-2378
9364435Apr 15, 2029in 2 yr 10 mo
ProductU-2378
10240152Oct 20, 2029in 3 yr 5 mo
SubstanceProductU-2378
8741866Oct 20, 2029in 3 yr 5 mo
U-2378
9234196Oct 20, 2029in 3 yr 5 mo
ProductU-2378
8802644Oct 21, 2030in 4 yr 5 mo
ProductU-2378
8158601Nov 10, 2030in 4 yr 6 mo
ProductU-2378
8168775Aug 10, 2032in 6 yr 3 mo
SubstanceProductU-2378
11079379Aug 27, 2035in 9 yr 4 mo
SubstanceProductU-2378
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.